Recurrent respiratory papillomatopathy
Conditions
Interventions
Observation group:N/A
Mixed control group:N/A
Sponsors
Beijing Tongren Hospital
Eligibility
Sex/Gender
Female
Age
9 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for the observation group: (1) Age 9-45 years old, divided into four age groups: 9-17 years old, 18-26 years old, 27-35 years old, and 36-45 years old (including the cut-off value) to match the cases in the control group; (2) female; (3) Papillomatous lesions can be seen in the respiratory tract, and recurrent respiratory papillomatosis is diagnosed, or papilloma is confirmed by pathology; (4) Have completed the three-dose standard immunization schedule and have been 7-12 months since the first dose; (5) The total number of surgeries before enrollment was divided into five ranges: 0-5, 6-10, 11-15, 16-20 (including the cut-off value) and more than 20 to match the cases in the control group; (6) Patients who are positive for HPV vaccine coverage type infection (i.e., HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 are positive for any type), and match control cases according to HPV type. 2. Inclusion criteria for the control group: (1) Age 9-45 years old, divided into four age groups: 9-17 years old, 18-26 years old, 27-35 years old, and 36-45 years old (including the cut-off value) for matching cases in the observation group; (2) female; (3) Papillomatous lesions can be seen in the respiratory tract, and recurrent respiratory papillomatosis is diagnosed, or papilloma is confirmed by pathology; (4) Previously or contemporaneously underwent surgery in our hospital and have not been vaccinated against HPV; (5) The number of surgeries before enrollment was divided into five ranges: 0-5, 6-10, 11-15, 16-20 (including the cut-off value) and more than 20 cases. (6) Patients who are positive for HPV vaccine coverage type infection (i.e., HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 are positive for any type), and the cases in the observation group are matched according to the HPV type.
Exclusion criteria
Exclusion criteria: (1) Those who have received other adjuvant therapy in the past, such as bevacizumab, interferon, traditional Chinese medicine, etc.; (2) Those with a history of gastrointestinal perforation, severe bleeding, arterial thromboembolism, chemical drugs, and radiotherapy in the past; (3) Patients with severe heart, liver and kidney insufficiency or other contraindications to drugs; (4) Those with a clear history of neurological or psychiatric disorders, such as epilepsy, dementia, and poor compliance; (5) Those who have been immunosuppressed or potentially immunosuppressed in the past, or are currently immunocompromised, or have been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases; (6) Those who have undergone splenectomy in the past; (7) Pregnant and lactating females who have no plans to become pregnant in the next 1 year; (8) Unable to complete regular endoscopy after surgery, incomplete medical records and imaging data, or refusal of the patient's family members and guardians to participate in this study; (9) Known hypersensitivity reaction to HPV vaccine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the rate of tumor proliferation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cohen grading;VHI score;GRBAS score;Evaluation of lung lesions;Assessment of dyspnea; | — |
Countries
China
Contacts
Public ContactJun Wang
Beijing Tongren Hospital
Outcome results
None listed